News
EQS-News: MEDICLIN ends successful 2024 financial year
Uni-Bio Science Group Limited Announces 2024 Annual Results
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending
Evolva Holding SA shareholders elect Clearway representatives to the Board of Directors
EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual
LivaNova to Announce First-Quarter 2025 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8
Natus Sensory Announces the US Launch of ICS® Dizcovery VNG at AAA 2025
Natus Sensory, the world leader in hearing and balance diagnostic systems, announces the official US launch of the ICS® Dizcovery VNG today at the American Academy of Audiology's Annual Convention
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Dexcom Appoints Jon Coleman as Chief Commercial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus
EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell
EQS-News: Abivax Announces Full Year 2024 Financial Results
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Inogen To Present at 24th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual